今日の臨床サポート

幽門狭窄症(小児科)

著者: 榊原裕史 東京都立小児総合医療センター 総合診療科

監修: 渡辺博 帝京大学老人保健センター

著者校正/監修レビュー済:2019/10/26

概要・推奨   

  1. 嘔吐で発症し、時間経過とともにその頻度は増加し、しばしば噴水様の非胆汁性嘔吐となる。
  1. 生後2週間から2カ月で発症し、男女比は4:1である。また第1子が3割を占める。
  1. 幽門筋の肥厚により生じる通過障害が原因である。
薬剤監修について:
オーダー内の薬剤用量は日本医科大学付属病院 薬剤部 部長 伊勢雄也 以下、林太祐、渡邉裕次、井ノ口岳洋、梅田将光による疑義照会のプロセスを実施、疑義照会の対象については著者の方による再確認を実施しております。
※薬剤中分類、用法、同効薬、診療報酬は、エルゼビアが独自に作成した薬剤情報であり、
著者により作成された情報ではありません。
尚、用法は添付文書より、同効薬は、薬剤師監修のもとで作成しております。
※薬剤情報の(適外/適内/⽤量内/⽤量外/㊜)等の表記は、エルゼビアジャパン編集部によって記載日時にレセプトチェックソフトなどで確認し作成しております。ただし、これらの記載は、実際の保険適用の査定において保険適用及び保険適用外と判断されることを保証するものではありません。また、検査薬、輸液、血液製剤、全身麻酔薬、抗癌剤等の薬剤は保険適用の記載の一部を割愛させていただいています。
(詳細はこちらを参照)
著者のCOI(Conflicts of Interest)開示:
榊原裕史 : 特に申告事項無し[2021年]
監修:渡辺博 : 特に申告事項無し[2021年]

改訂のポイント:
  1. 妊娠中・授乳中のマクロライド使用と肥厚性幽門狭窄症の発症に関するメタアナリシスを追加した。

病態・疫学・診察

疾患情報(疫学・病態)  
  1. 嘔吐で発症し、時間経過とともにその頻度は増加し、しばしば噴水様の非胆汁性嘔吐となる[1]
  1. 幽門筋の肥厚により生じる通過障害が原因である[1]
  1. 生後2週間から2カ月で発症し、男女比は4:1である。また第1子が3割を占める[1]
  1. 発症率は1,000人あたり2~3.5人であるが、地域差、人種差がみられる。白色人種で多く、アジア人では少ない。また近年、発症率低下の報告が散見される[1][2][3]
  1. 家族内の集積があり、発症率は一卵性双胎で約200倍、二卵性双胎、兄弟で約20倍と報告されている[4]
  1. 生後2週間までのエリスロマイシン投与との関連が指摘されている。またアジスロマイシンでも症例報告がみられる[5][6][7]
  1. 近年のメタアナリシスによれば、妊娠中・授乳中のマクロライド使用と肥厚性幽門狭窄症の発症には有意な関連はない[8]
  1. 遺伝的素因と環境要因により発症すると考えられており、関連する遺伝子座がいくつか報告されているが、正確な機序はいまだ明らかではない[9]
問診・診察のポイント  
  1. 生後2週間から2カ月の嘔吐を認める患児では、常に念頭に置く必要がある。

これより先の閲覧には個人契約のトライアルまたはお申込みが必要です。

最新のエビデンスに基づいた二次文献データベース「今日の臨床サポート」。
常時アップデートされており、最新のエビデンスを各分野のエキスパートが豊富な図表や処方・検査例を交えて分かりやすく解説。日常臨床で遭遇するほぼ全ての症状・疾患から薬剤・検査情報まで瞬時に検索可能です。

まずは15日間無料トライアル
本サイトの知的財産権は全てエルゼビアまたはコンテンツのライセンサーに帰属します。私的利用及び別途規定されている場合を除き、本サイトの利用はいかなる許諾を与えるものでもありません。 本サイト、そのコンテンツ、製品およびサービスのご利用は、お客様ご自身の責任において行ってください。本サイトの利用に基づくいかなる損害についても、エルゼビアは一切の責任及び賠償義務を負いません。 また、本サイトの利用を以て、本サイト利用者は、本サイトの利用に基づき第三者に生じるいかなる損害についても、エルゼビアを免責することに合意したことになります。  本サイトを利用される医学・医療提供者は、独自の臨床的判断を行使するべきです。本サイト利用者の判断においてリスクを正当なものとして受け入れる用意がない限り、コンテンツにおいて提案されている検査または処置がなされるべきではありません。 医学の急速な進歩に鑑み、エルゼビアは、本サイト利用者が診断方法および投与量について、独自に検証を行うことを推奨いたします。

文献 

著者: Marta Hernanz-Schulman
雑誌名: Radiology. 2003 May;227(2):319-31. doi: 10.1148/radiol.2272011329. Epub 2003 Mar 13.
Abstract/Text Infantile hypertrophic pyloric stenosis is a common condition affecting young infants; despite its frequency, it has been recognized only for a little over a century, and its etiology remains unknown. Nevertheless, understanding of the condition and of effective treatment have undergone a remarkable evolution in the 20th century, reducing the mortality rate from over 50% to nearly 0%. The lesion is characterized by gastric outlet obstruction and multiple anatomic abnormalities of the pyloric antrum. The antropyloric muscle is abnormally thickened and innervated, and the intervening lumen is obstructed by crowded and redundant mucosa. Recognition of the obstructive role of the mucosa led to discovery of effective surgical treatment. Accurate clinical diagnosis in patients in whom a thickened antropyloric muscle is not readily palpable can be difficult, resulting in delayed diagnosis and can lead to emaciation and electrolyte imbalance, making the patient a suboptimal surgical candidate. Current imaging techniques, particularly sonography, are noninvasive and accurate for identification of infantile hypertrophic pyloric stenosis. Successful imaging requires understanding of anatomic changes that occur in patients with this condition and plays an integral role in patient care. Accurate, rapid, noninvasive imaging techniques facilitate rapid referral of vomiting infants and prompt surgical treatment of more suitable surgical candidates.

Copyright RSNA, 2003
PMID 12637675  Radiology. 2003 May;227(2):319-31. doi: 10.1148/radiol.・・・
著者: T Sommerfield, J Chalmers, G Youngson, C Heeley, M Fleming, G Thomson
雑誌名: Arch Dis Child. 2008 Dec;93(12):1007-11. doi: 10.1136/adc.2007.128090. Epub 2008 Feb 19.
Abstract/Text BACKGROUND: The aetiology of infantile hypertrophic pyloric stenosis (IHPS) has not been fully elucidated. Since the 1990s, a sharp decline in IHPS has been reported in various countries. Recent research from Sweden reported a correlation between falling rates of IHPS and of sudden infant death syndrome (SIDS). This was attributed to a reduction in the number of infants sleeping in the prone position following the "Back to Sleep" campaign.
OBJECTIVES: To describe the changing epidemiology of IHPS in Scotland, to examine the relationship between IHPS and SIDS rates and to examine trends in other factors that may explain the observed reduction in IHPS incidence.
DESIGN: Incidence rates of IHPS and SIDS were derived from routine data and their relationship analysed. Trends in mean maternal age, maternal smoking, mean birth weight and breastfeeding rates were also examined.
SETTING: The whole of Scotland between 1981 and 2004.
RESULTS: IHPS incidence fell from 4.4 to 1.4 per 1000 live births in Scotland between 1981 and 2004. Rates were consistently higher in males, although the overall incidence patterns in males and females were similar. Rates showed a positive relationship with deprivation. The fall in the incidence of IHPS preceded the fall in SIDS by 2 years and the incidence of SIDS displayed less variability than that of IHPS. Significant temporal trends were also observed in other maternal and infant characteristics.
CONCLUSION: There has been a marked reduction in Scotland's IHPS incidence, but this is unlikely to be a consequence of a change in infant sleeping position.

PMID 18285388  Arch Dis Child. 2008 Dec;93(12):1007-11. doi: 10.1136/a・・・
著者: Jan de Laffolie, Salmai Turial, Matthias Heckmann, Klaus-Peter Zimmer, Felix Schier
雑誌名: Pediatrics. 2012 Apr;129(4):e901-6. doi: 10.1542/peds.2011-2845. Epub 2012 Mar 19.
Abstract/Text BACKGROUND AND OBJECTIVE: The incidence of infantile hypertrophic pyloric stenosis (IHPS) is highly variable over time and geographic regions. A decline in IHPS incidence was recently reported in Sweden, the United States, Denmark, and Scotland. In Sweden, the IHPS decline seemed to be concurrent with a declining incidence in sudden infant death syndrome (SIDS), which suggested a common cause; the latter was attributed to campaigns against the prone sleeping position. We investigated the time course of the IHPS incidence in all German federal states (N = 16) between 2000 and 2008. We examined correlations between the IHPS incidence and the SIDS incidence.
METHODS: Data were extracted from the public report of health (Gesundheitsberichterstattung des Bundes). We collected the numbers of IHPS (International Classification of Diseases, 10th Revision [ICD-10], code 40.0), SIDS (ICD-10, R95), and live births (LB; male/female) in each federal state for 2000-2008.
RESULTS: The IHPS incidence declined in Germany from 2000 (3.2086/1000 LB [range: 1.67-5.33]) to 2008 (2.0175/1000 LB [1.74-3.72]; P = .005). The recorded incidence was highly variable in different federal states and over time. The SIDS incidence also declined during the same time period (2000, median: 0.759/1000 LB [interquartile range: 0.54-1.029]; 2008, median: 0.416/1000 LB [interquartile range: 0.285-0.6485]; P = .0255). However, the SIDS regional distribution was different from that of IHPS.
CONCLUSIONS: The IHPS incidence declined by ∼38% nationwide. A parallel decline in SIDS displayed a different pattern in regional distribution; thus, a common cause was unlikely. The regional differences indicated that etiologic factors remained unresolved.

PMID 22430445  Pediatrics. 2012 Apr;129(4):e901-6. doi: 10.1542/peds.2・・・
著者: Camilla Krogh, Thea K Fischer, Line Skotte, Robert J Biggar, Nina Øyen, Axel Skytthe, Sanne Goertz, Kaare Christensen, Jan Wohlfahrt, Mads Melbye
雑誌名: JAMA. 2010 Jun 16;303(23):2393-9. doi: 10.1001/jama.2010.784.
Abstract/Text CONTEXT: Pyloric stenosis is the most common condition requiring surgery in the first months of life. Case reports have suggested familial aggregation, but to what extent this is caused by common environment or inheritance is unknown.
OBJECTIVES: To investigate familial aggregation of pyloric stenosis from monozygotic twins to fourth-generation relatives according to sex and maternal and paternal contributions and to estimate disease heritability.
DESIGN, SETTING, AND PATIENTS: Population-based cohort study of 1,999,738 children born in Denmark between 1977 and 2008 and followed up for the first year of life, during which 3362 children had surgery for pyloric stenosis.
MAIN OUTCOME MEASURE: Familial aggregation of pyloric stenosis, evaluated by rate ratios.
RESULTS: The incidence rate (per 1000 person-years) of pyloric stenosis in the first year of life was 1.8 for singletons and 3.1 for twins. The rate ratios of pyloric stenosis were 182 (95% confidence interval [CI], 70.7-467) for monozygotic twins, 29.4 (95% CI, 9.45-91.5) for dizygotic twins, 18.5 (95% CI, 13.7-25.1) for siblings, 4.99 (95% CI, 2.59-9.65) for half-siblings, 3.06 (95% CI, 2.10-4.44) for cousins, and 1.60 (95% CI, 0.51-4.99) for half-cousins. We found no difference in rate ratios for maternal and paternal relatives of children with pyloric stenosis and no difference according to sex of cohort member or sex of relative. The heritability of pyloric stenosis was 87%.
CONCLUSION: Pyloric stenosis in Danish children shows strong familial aggregation and heritability.

PMID 20551410  JAMA. 2010 Jun 16;303(23):2393-9. doi: 10.1001/jama.201・・・
著者: B E Mahon, M B Rosenman, M B Kleiman
雑誌名: J Pediatr. 2001 Sep;139(3):380-4. doi: 10.1067/mpd.2001.117577.
Abstract/Text OBJECTIVES: To evaluate the risk for infantile hypertrophic pyloric stenosis (IHPS) among infants prescribed systemic erythromycin, infants prescribed a course of erythromycin ophthalmic ointment, and infants whose mothers were prescribed a macrolide antibiotic during pregnancy.
STUDY DESIGN: Retrospective cohort study of infants born at an urban hospital from June 1993 through December 1999.
RESULTS: Of 14,876 eligible infants, 43 (0.29%) developed IHPS. Infants prescribed systemic erythromycin had increased risk of IHPS, with the highest risk in the first 2 weeks of age (relative risk = 10.51 for erythromycin in first 2 weeks, 95% CI 4.48, 24.66). Erythromycin ophthalmic ointment for conjunctivitis was not associated with increased risk of IHPS. Maternal macrolide antibiotics within 10 weeks of delivery may have been associated with higher risk of IHPS but the data were not conclusive.
CONCLUSIONS: This study confirms an association between systemic erythromycin in infants and subsequent IHPS, with the highest risk in the first 2 weeks of age. No association was found with erythromycin ophthalmic ointment. A possible association with maternal macrolide therapy in late pregnancy requires further study. Systemic erythromycin should be used with prudence in early infancy.

PMID 11562617  J Pediatr. 2001 Sep;139(3):380-4. doi: 10.1067/mpd.2001・・・
著者: Wynne Morrison
雑誌名: Pediatr Infect Dis J. 2007 Feb;26(2):186-8. doi: 10.1097/01.inf.0000253063.87338.60.
Abstract/Text Seven-week-old 32-week premature triplets were hospitalized because of rhinorrhea, cough with color change and posttussive emesis. One infant had a positive direct fluorescent antibody test for Bordetella pertussis, so all were treated with 5 days of azithromycin. Two of the infants were subsequently diagnosed with hypertrophic pyloric stenosis and underwent surgical pyloromyotomies 6 and 7 weeks, respectively, after the initial admission.

PMID 17259889  Pediatr Infect Dis J. 2007 Feb;26(2):186-8. doi: 10.109・・・
著者: Matthew D Eberly, Matilda B Eide, Jennifer L Thompson, Cade M Nylund
雑誌名: Pediatrics. 2015 Mar;135(3):483-8. doi: 10.1542/peds.2014-2026.
Abstract/Text BACKGROUND AND OBJECTIVE: Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS). The risk with azithromycin remains unknown. We evaluated the association between exposure to oral azithromycin and erythromycin and subsequent development of IHPS.
METHODS: A retrospective cohort study of children born between 2001 and 2012 was performed utilizing the military health system database. Infants prescribed either oral erythromycin or azithromycin as outpatients in the first 90 days of life were evaluated for development of IHPS. Specific diagnostic and procedural codes were used to identify cases of IHPS.
RESULTS: A total of 2466 of 1 074 236 children in the study period developed IHPS. Azithromycin exposure in the first 14 days of life demonstrated an increased risk of IHPS (adjusted odds ratio [aOR], 8.26; 95% confidence interval [CI], 2.62-26.0); exposure between 15 and 42 days had an aOR of 2.98 (95% CI, 1.24-7.20). An association between erythromycin and IHPS was also confirmed. Exposure to erythromycin in the first 14 days of life had an aOR of 13.3 (95% CI, 6.80-25.9), and 15 to 42 days of life, aOR 4.10 (95% CI, 1.69-9.91). There was no association with either macrolide between 43 and 90 days of life.
CONCLUSIONS: Ingestion of oral azithromycin and erythromycin places young infants at increased risk of developing IHPS. This association is strongest if the exposure occurred in the first 2 weeks of life, but persists although to a lesser degree in children between 2 and 6 weeks of age.

published in the public domain by the American Academy of Pediatrics.
PMID 25687145  Pediatrics. 2015 Mar;135(3):483-8. doi: 10.1542/peds.20・・・
著者: Mohammed Abdellatif, Sherief Ghozy, Mohamed Gomaa Kamel, Sameh Samir Elawady, Mohamed Mohy Eldeen Ghorab, Andrew Wassef Attia, Truong Thi Le Huyen, Diep Trong Vien Duy, Kenji Hirayama, Nguyen Tien Huy
雑誌名: Eur J Pediatr. 2019 Mar;178(3):301-314. doi: 10.1007/s00431-018-3287-7. Epub 2018 Nov 23.
Abstract/Text Macrolides are bacteriostatic antibiotics with a broad spectrum of activity against Gram-positive bacteria. The aim of this study was to systematically review and meta-analyze the association between infantile hypertrophic pyloric stenosis (IHPS) and macrolides. Nine databases were searched systematically for studies with information on the association between macrolides and IHPS. We combined findings using random effects models. Our study revealed 18 articles investigating the association between macrolides and IHPS. There was a significant association between the development of IHPS and erythromycin (2.38, 1.06-5.39). The association was strong when erythromycin was used during the first 2 weeks of life (8.14, 4.29-15.45). During breastfeeding, use of macrolides showed no significant association with IHPS in infants (0.96, 0.61-1.53). IHPS was not associated with erythromycin (1.11, 0.9-1.36) or macrolides use during pregnancy (1.15, 0.98-1.36).Conclusions: There is an association between erythromycin use during infancy and developing IHPS in infants. However, no significant association was found between macrolides use during pregnancy or breastfeeding. Additional large studies are needed to further evaluate potential association with macrolide use. What is known? • Erythromycin intake in the first 2 weeks of life is associated with an increased risk of pyloric stenosis. What is New? • There is currently no evidence of significant association between macrolides use during pregnancy or breastfeeding and pyloric stenosis.

PMID 30470884  Eur J Pediatr. 2019 Mar;178(3):301-314. doi: 10.1007/s0・・・
著者: Eddie Chung
雑誌名: Arch Dis Child. 2008 Dec;93(12):1003-4. doi: 10.1136/adc.2008.141499.
Abstract/Text
PMID 19028966  Arch Dis Child. 2008 Dec;93(12):1003-4. doi: 10.1136/ad・・・
著者: Mary Jane Piroutek, Lance Brown, Andrea W Thorp
雑誌名: Clin Pediatr (Phila). 2012 Mar;51(3):214-8. doi: 10.1177/0009922811431159. Epub 2011 Dec 12.
Abstract/Text OBJECTIVE: To describe the incidence of bilious vomiting in infants with infantile hypertrophic pyloric stenosis that presented to a pediatric emergency department.
METHODS: A retrospective medical record review included all infants who presented to our level 1 pediatric emergency department from January 1, 2005, through December 31, 2009, who were diagnosed intraoperatively with infantile hypertrophic pyloric stenosis. Emesis was determined to be bilious if the vomit was described as "green," "containing bile," or "bilious."
RESULTS: The authors identified 354 infants with infantile hypertrophic pyloric stenosis. The median age was 4 weeks 6 days (range = 11 days to 13 weeks). Bilious emesis was encountered in 1.4% (5/354; 95% confidence interval = 0.5% to 3.2%). The pyloric thickness measurements on ultrasound were significantly smaller in those with bilious emesis compared with those without bilious emesis (z score = 2.64; P = .014).
CONCLUSION: Bilious emesis was the presenting symptom in a small proportion of infants with infantile hypertrophic pyloric stenosis.

PMID 22166750  Clin Pediatr (Phila). 2012 Mar;51(3):214-8. doi: 10.117・・・
著者: Chien-Yu Lin, Hsin Chi, Chyong-Hsin Hsu, Fu-Yuan Huang, Hung-Chang Lee, Nan-Chang Chiu
雑誌名: J Pediatr. 2014 Feb;164(2):423.e1. doi: 10.1016/j.jpeds.2013.08.052. Epub 2013 Oct 8.
Abstract/Text
PMID 24112865  J Pediatr. 2014 Feb;164(2):423.e1. doi: 10.1016/j.jpeds・・・
著者: J S Janik, E R Wayne, J P Janik
雑誌名: Arch Pediatr Adolesc Med. 1996 Feb;150(2):223-4.
Abstract/Text
PMID 8556133  Arch Pediatr Adolesc Med. 1996 Feb;150(2):223-4.
著者: W K Rohrschneider, H Mittnacht, K Darge, J Tröger
雑誌名: Pediatr Radiol. 1998 Jun;28(6):429-34.
Abstract/Text OBJECTIVE: To compare the morphological and functional US appearance of the pylorus in healthy infants with those suffering from idiopathic hypertrophic pyloric stenosis (IHPS) in order to determine the pathological limits and to find out the most discriminating morphometric parameter.
MATERIALS AND METHODS: The pylorus of 84 asymptomatic infants was prospectively evaluated with respect to morphology (pyloric length, pyloric diameter, muscle thickness and pyloric volume) and function (gastric peristalsis and emptying, pyloric opening and the fluid passage). Results were compared with 85 patients with proven IHPS.
RESULTS: In every normal infant we observed frequent pyloric opening with passage of gastric contents and quick gastric emptying. All infants with proven IHPS presented with a permanently closed pylorus and exaggerated, retrograde gastric peristalsis. For each of the four parameters, highly significant differences (P < 0.0001) were found between the control and IHPS groups. Pathological limits were 3 mm for muscle thickness (accuracy 100 %), 15 mm for pyloric length (accuracy 94 %), 11 mm for pyloric diameter (accuracy 92 %) and 12 ml for pyloric volume (accuracy 96 %).
CONCLUSIONS: Evaluation of pyloric function plays an important role in the diagnosis of IHPS. The morphometric parameters are highly accurate in differentiating IHPS from a normal pylorus, muscle thickness being the most discriminating parameter.

PMID 9634457  Pediatr Radiol. 1998 Jun;28(6):429-34.
著者: Corey W Iqbal, Douglas C Rivard, Vincent E Mortellaro, Susan W Sharp, Shawn D St Peter
雑誌名: J Pediatr Surg. 2012 Aug;47(8):1542-7. doi: 10.1016/j.jpedsurg.2012.03.068.
Abstract/Text INTRODUCTION: Pyloric thickness of 3 mm or higher and length of 15 mm or higher by ultrasonography (US) is widely accepted as diagnostic criteria for pyloric stenosis (PS). However, infants presenting at earlier ages are held to this same criteria, which may not be applicable.
METHODS: Retrospective review was conducted on patients evaluated with pyloric US to rule out PS from May 2010 through December 2010. Pearson correlation was used to detect an association between weight and age with pyloric thickness and length. Sensitivity and specificity for US parameters were determined.
RESULTS: Three hundred four patients underwent 318 ultrasounds, of which 67 had PS. Of those with PS, age and weight had a positive correlation with thickness (P < .007), and age positively correlated with length (P < .001). In patients with and without PS, there was a negative correlation for both age and weight with thickness (P < .02). Those who did not have PS held a stronger negative correlation between age and thickness (P = .002). Overall, US had a 100% sensitivity and specificity for PS. Thickness of 3 mm or higher was 100% sensitive and 99% specific, and pyloric length of 15 mm or higher was 100% sensitive and 97% specific.
CONCLUSIONS: Although significant associations between age and weight with pyloric thickness and length may exist, our data indicate that this does not have an impact on the diagnostic criteria for PS.

Copyright © 2012 Elsevier Inc. All rights reserved.
PMID 22901914  J Pediatr Surg. 2012 Aug;47(8):1542-7. doi: 10.1016/j.j・・・
著者: Hisayoshi Kawahara, Yuichi Takama, Hideki Yoshida, Hiroshi Nakai, Hiroomi Okuyama, Akio Kubota, Norikazu Yoshimura, Shinobu Ida, Akira Okada
雑誌名: J Pediatr Surg. 2005 Dec;40(12):1848-51. doi: 10.1016/j.jpedsurg.2005.08.025.
Abstract/Text BACKGROUND/PURPOSE: Laparoscopic pyloromyotomy has recently gained wide acceptance as the optimum treatment of infantile hypertrophic pyloric stenosis (IHPS). However, medical treatment may be superior to laparoscopic surgery in invasiveness. The efficacy of our regimen of intravenous atropine therapy for IHPS was assessed in comparison with surgical treatment.
METHODS: Medical treatment was initially chosen for 52 (61%) of 85 infants with IHPS at our institute between 1996 and 2004. Atropine was given intravenously at 0.01 mg/kg 6 times a day before feeding. When vomiting ceased and the infants were able to ingest 150 mL/kg per day of formula after stepwise increases in the feeding volume, they were given 0.02 mg/kg atropine 6 times a day orally, and the dose was decreased stepwise.
RESULTS: Of the 52 patients, 45 (87%) ceased projectile vomiting with treatment using intravenous (median, 7 days) and subsequent oral (median, 44 days) atropine administration. The median hospital stay was 13 days (6-36), and no significant complications were encountered during atropine therapy. The remaining 7 patients required surgery. Of 40 who underwent surgery, 4 had wound infections and 1 with hemophilia had postoperative hemorrhagic shock. The patients who underwent successful atropine therapy had body weights comparable with those who underwent surgery at the age of 1 year.
CONCLUSIONS: The high success rate of intravenous atropine therapy for IHPS suggests that this therapy is an effective alternative to pyloromyotomy if the length of the hospital stay and the necessity of continuing oral atropine medication are accepted.

PMID 16338303  J Pediatr Surg. 2005 Dec;40(12):1848-51. doi: 10.1016/j・・・
著者: Anita Erika Mercer, Robert Phillips
雑誌名: Arch Dis Child. 2013 Jun;98(6):474-7. doi: 10.1136/archdischild-2013-303655.
Abstract/Text
PMID 23661669  Arch Dis Child. 2013 Jun;98(6):474-7. doi: 10.1136/arch・・・
著者: Sabina Siddiqui, R Eric Heidel, Carlos A Angel, Alfred P Kennedy
雑誌名: J Pediatr Surg. 2012 Jan;47(1):93-8. doi: 10.1016/j.jpedsurg.2011.10.026.
Abstract/Text PURPOSE: Open pyloromyotomy remains as the criterion standard treatment for hypertrophic pyloric stenosis with the laparoscopic approach rapidly gaining adoption. We present a prospective, randomized trial between the 2 approaches.
METHODS: After institutional review board approval, 98 patients with hypertrophic pyloric stenosis were consecutively randomized to either open or laparoscopic pyloromyotomy. Postoperative and hospital course were evaluated by review of the hospital records and long-term follow-up with scripted telephone survey using Likert scales. The length of operating room time, surgical procedure, postoperative stay, time to refeeding, and complications were evaluated. Secondary outcomes of cosmetic results and parental satisfaction were determined.
RESULTS: Ninety-eight patients were enrolled during a 4-year period. There were no significant differences between 2 groups on all primary outcomes. There were 3 complications in the open group-a wound dehiscence, a surgical site infection, and a gastric serosal tear-and 2 complications in the laparoscopic group-mucosal perforation and a suture granuloma. In long-term follow-up on 72 patients (56 months), parents described significant cosmetic results with laparoscopic approach.
CONCLUSIONS: There was no difference in operating time, hospital stay, or refeeding patterns between open and laparoscopic pyloromyotomy. The complication rates were similar between the 2 methods. However, long-term cosmetic results were significantly superior in the laparoscopic group.

Copyright © 2012 Elsevier Inc. All rights reserved.
PMID 22244399  J Pediatr Surg. 2012 Jan;47(1):93-8. doi: 10.1016/j.jpe・・・

ページ上部に戻る

戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから